AMETEK (NYSE:AME) Downgraded to "Hold" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded AMETEK from a "buy" to a "hold" rating in a Sunday note to investors.
• Despite the downgrade, most analysts remain bullish on the stock, with a consensus rating of Moderate Buy and an average price target of $252.33.
• AMETEK recently reported better-than-expected quarterly results, with EPS of $1.97 versus $1.90 expected and revenue of $1.93 billion, while also raising guidance for FY2026.

AMETEK (NYSE:AME - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Sunday.

Other equities research analysts have also recently issued reports about the company. BMO Capital Markets assumed coverage on AMETEK in a report on Friday, March 27th. They issued an "outperform" rating and a $253.00 target price on the stock. Royal Bank Of Canada increased their price target on AMETEK from $259.00 to $260.00 and gave the company an "outperform" rating in a research note on Friday, May 1st. Robert W. Baird set a $244.00 price objective on AMETEK in a research note on Friday, May 1st. KeyCorp increased their target price on AMETEK from $235.00 to $260.00 and gave the company an "overweight" rating in a research report on Wednesday, February 4th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of AMETEK in a report on Wednesday, January 21st. They issued a "buy" rating and a $271.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $252.33.

AMETEK Price Performance

AME stock opened at $232.17 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 0.72 and a current ratio of 1.14. The company's fifty day moving average price is $225.75 and its 200-day moving average price is $214.31. AMETEK has a one year low of $170.95 and a one year high of $243.18. The company has a market capitalization of $53.21 billion, a PE ratio of 35.07, a price-to-earnings-growth ratio of 3.26 and a beta of 1.03.

AMETEK (NYSE:AME - Get Free Report) last posted its earnings results on Thursday, April 30th. The technology company reported $1.97 earnings per share for the quarter, beating the consensus estimate of $1.90 by $0.07. The company had revenue of $1.93 billion during the quarter, compared to analysts' expectations of $1.91 billion. AMETEK had a net margin of 20.11% and a return on equity of 16.63%. AMETEK's quarterly revenue was up 11.3% on a year-over-year basis. During the same period last year, the company posted $1.75 earnings per share. AMETEK has set its FY 2026 guidance at 7.940-8.140 EPS and its Q2 2026 guidance at 1.960-2.000 EPS. On average, equities analysts anticipate that AMETEK will post 8.12 EPS for the current fiscal year.

Insider Activity at AMETEK

In other news, Director Thomas A. Amato sold 530 shares of the business's stock in a transaction that occurred on Tuesday, March 24th. The stock was sold at an average price of $216.78, for a total transaction of $114,893.40. Following the transaction, the director owned 4,480 shares of the company's stock, valued at approximately $971,174.40. The trade was a 10.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.54% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Florida Financial Advisors LLC boosted its stake in shares of AMETEK by 2.2% during the 4th quarter. Florida Financial Advisors LLC now owns 1,974 shares of the technology company's stock worth $406,000 after purchasing an additional 43 shares during the period. Plato Investment Management Ltd raised its position in AMETEK by 0.4% in the 4th quarter. Plato Investment Management Ltd now owns 10,751 shares of the technology company's stock worth $2,218,000 after purchasing an additional 47 shares during the period. Allegiance Financial Group Advisory Services LLC lifted its stake in AMETEK by 4.0% in the fourth quarter. Allegiance Financial Group Advisory Services LLC now owns 1,254 shares of the technology company's stock worth $257,000 after purchasing an additional 48 shares during the last quarter. Washington Trust Advisors Inc. boosted its position in shares of AMETEK by 6.3% during the fourth quarter. Washington Trust Advisors Inc. now owns 850 shares of the technology company's stock valued at $175,000 after buying an additional 50 shares during the period. Finally, Root Financial Partners LLC boosted its position in shares of AMETEK by 18.3% during the first quarter. Root Financial Partners LLC now owns 323 shares of the technology company's stock valued at $69,000 after buying an additional 50 shares during the period. Institutional investors own 87.43% of the company's stock.

About AMETEK

AMETEK, Inc is a global manufacturer of electronic instruments and electromechanical devices that serves a broad range of industries. Headquartered in Berwyn, Pennsylvania, the company designs and produces precision instruments, electronic measurement devices, specialty sensors, and electric motors and motion control systems. Its product portfolio includes analytical and monitoring instruments, calibration equipment, power supplies, embedded electronics, and industrial motors and drives used for critical applications.

The company operates through two primary business platforms — an electronic instruments group focused on analytical, test and measurement and sensor products, and an electromechanical group that supplies motors, actuators, and related power and motion solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.